Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | HCAR3 | P49019 | 3/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 6/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | VCAM1 | P19320 | 2/20 | 0.40 |
| ▸ | CASP6 | P55212 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20150171 | 0.84 | VCAM1 (0.60) | ALDH1A1TSHRKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL26121327 | 0.83 | CYP19A1 (0.40) | ALDH1A1TSHRHCAR3CYP19A1KMT2A | |
| SCHEMBL26118896 | 0.80 | TSHR (0.50) | ALDH1A1TSHRCYP19A1SMN1; SMN2VCAM1 | |
| SCHEMBL29686179 | 0.80 | TSHR (0.50) | ALDH1A1TSHRCYP19A1SMN1; SMN2VCAM1 | |
| SCHEMBL20225763 | 0.78 | TSHR (0.53) | ALDH1A1TSHRCYP19A1PKMMAPT | |
| SCHEMBL20150149 | 0.77 | CYP19A1 (0.49) | ALDH1A1CYP19A1MAPT | |
| SCHEMBL29739895 | 0.77 | CYP19A1 (0.49) | ALDH1A1CYP19A1MAPT | |
| SCHEMBL3617121 | 0.77 | CYP19A1 (0.50) | ALDH1A1CYP19A1ATM | |
| SCHEMBL20150169 | 0.75 | THRB (0.40) | ALDH1A1HCAR3CYP19A1KMT2AMEN1 | |
| SCHEMBL11697178 | 0.75 | HCAR3 (0.74) | ALDH1A1TSHRHCAR3SMN1; SMN2VCAM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180134700-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180134700-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | ALDH1A1 4827/4885TSHR 1652/4885HCAR3 3413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.